Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Direct Payment

$120,000.00

A toolkit of repressive elements for cell-type-specific control of AAV transgene expression

FY 2025-26

Summary
Adeno-associated viruses (AAVs) are vehicles that have been adapted to deliver gene therapies to the brain, but these therapies often reach cells in which they are not needed or may be harmful. This research aims to improve the target specificity of AAV therapies within the brain to enhance their clinical safety. Existing therapies commonly incorporate genetic ON switches that activate the therapy once it enters target cells, but this approach has suffered from a trade-off between activity and specificity. To address this limitation, I aim to introduce new genetic OFF switches, called synthetic repressive elements (SREs), that can turn off therapeutic genes in designated cell types by harnessing the endogenous microRNA gene silencing mechanism. To achieve this, I am building a large-scale screening platform that generates SREs and measures their efficacy across the brain at the single-cell level (Aim 1). Using this platform, I will optimize, validate, and catalog the most promising candidates to generate a toolkit of SREs with confirmed cell-type specificity, which I will share with the neuroscience community through public repositories (Aim 2). Lastly, I will investigate the synergistic efficacy of these SREs with cell-type-specific genetic ON switches by directing AAV activity to rare cell populations in the brain (Aim 3). The resulting SRE toolkit will provide the field with validated and characterized AAV control elements that can be readily used for diverse gene delivery applications in the brain. By reducing the level of unwanted therapeutic activity in off-target cells, this toolkit aims to enhance the safe development of preclinical AAV therapies. The successful completion of this project will provide a new avenue toward safer gene therapy applications for a broad range of human brain diseases.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Illinois, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
556156
Name
Bel Ari
Region
Illinois
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
A toolkit of repressive elements for cell-type-specific control of AAV transgene expression
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Adeno-Associated Virus (Aav); Bioinformatics; Brain; Gene Therapy; Human; Library Pool; Microrna Target Sites; Mouse; Single-Cell Rna Sequencing; Transcriptomics
Abstract
Adeno-associated viruses (AAVs) are vehicles that have been adapted to deliver gene therapies to the brain, but these therapies often reach cells in which they are not needed or may be harmful. This research aims to improve the target specificity of AAV therapies within the brain to enhance their clinical safety. Existing therapies commonly incorporate genetic ON switches that activate the therapy once it enters target cells, but this approach has suffered from a trade-off between activity and specificity. To address this limitation, I aim to introduce new genetic OFF switches, called synthetic repressive elements (SREs), that can turn off therapeutic genes in designated cell types by harnessing the endogenous microRNA gene silencing mechanism. To achieve this, I am building a large-scale screening platform that generates SREs and measures their efficacy across the brain at the single-cell level (Aim 1). Using this platform, I will optimize, validate, and catalog the most promising candidates to generate a toolkit of SREs with confirmed cell-type specificity, which I will share with the neuroscience community through public repositories (Aim 2). Lastly, I will investigate the synergistic efficacy of these SREs with cell-type-specific genetic ON switches by directing AAV activity to rare cell populations in the brain (Aim 3). The resulting SRE toolkit will provide the field with validated and characterized AAV control elements that can be readily used for diverse gene delivery applications in the brain. By reducing the level of unwanted therapeutic activity in off-target cells, this toolkit aims to enhance the safe development of preclinical AAV therapies. The successful completion of this project will provide a new avenue toward safer gene therapy applications for a broad range of human brain diseases.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bel, Ari
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
Direct Payment - $120,000 Grant (2025-26) | Canada Spends